PRODUCTID	PRODUCTNDC	PRODUCTTYPENAME	PROPRIETARYNAME	PROPRIETARYNAMESUFFIX	NONPROPRIETARYNAME	DOSAGEFORMNAME	ROUTENAME	STARTMARKETINGDATE	ENDMARKETINGDATE	MARKETINGCATEGORYNAME	APPLICATIONNUMBER	LABELERNAME	SUBSTANCENAME	ACTIVE_NUMERATOR_STRENGTH	ACTIVE_INGRED_UNIT	PHARM_CLASSES	DEASCHEDULE	NDC_EXCLUDE_FLAG	LISTING_RECORD_CERTIFIED_THROUGH
0002-0800_662164fd-5ea0-4a08-bfd1-6b08bdd73342	0002-0800	HUMAN OTC DRUG	Sterile Diluent		diluent	INJECTION, SOLUTION	SUBCUTANEOUS	19870710		BLA	BLA018781	Eli Lilly and Company	WATER	1	mL/mL			N	20221231
0002-1200_480fceef-6596-4478-97de-677c155506b3	0002-1200	HUMAN PRESCRIPTION DRUG	Amyvid		Florbetapir F 18	INJECTION, SOLUTION	INTRAVENOUS	20120601		NDA	NDA202008	Eli Lilly and Company	FLORBETAPIR F-18	51	mCi/mL	Positron Emitting Activity [MoA], Radioactive Diagnostic Agent [EPC]		N	20221231
0002-1210_151a431b-f07b-4959-b6fa-c41ff80364c8	0002-1210	HUMAN PRESCRIPTION DRUG	TAUVID		Flortaucipir F-18	INJECTION, SOLUTION	INTRAVENOUS	20200528		NDA	NDA212123	Eli Lilly and Company	FLORTAUCIPIR F-18	51	mCi/mL			N	20221231
0002-1433_69bd3896-91f6-4960-8538-2880159588c6	0002-1433	HUMAN PRESCRIPTION DRUG	Trulicity		Dulaglutide	INJECTION, SOLUTION	SUBCUTANEOUS	20140918		BLA	BLA125469	Eli Lilly and Company	DULAGLUTIDE	.75	mg/.5mL	GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]		N	20231231
0002-1434_69bd3896-91f6-4960-8538-2880159588c6	0002-1434	HUMAN PRESCRIPTION DRUG	Trulicity		Dulaglutide	INJECTION, SOLUTION	SUBCUTANEOUS	20140918		BLA	BLA125469	Eli Lilly and Company	DULAGLUTIDE	1.5	mg/.5mL	GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]		N	20231231
0002-1436_bec46346-20b5-4dbe-bac3-b8564e906941	0002-1436	HUMAN PRESCRIPTION DRUG	EMGALITY		galcanezumab-gnlm	INJECTION, SOLUTION	SUBCUTANEOUS	20180927		BLA	BLA761063	Eli Lilly and Company	GALCANEZUMAB	120	mg/mL			N	20221231
0002-1445_8ddfcec2-6a11-471d-92da-ea6a7365373f	0002-1445	HUMAN PRESCRIPTION DRUG	TALTZ		ixekizumab	INJECTION, SOLUTION	SUBCUTANEOUS	20160322		BLA	BLA125521	Eli Lilly and Company	IXEKIZUMAB	80	mg/mL	Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]		N	20231231
0002-2236_69bd3896-91f6-4960-8538-2880159588c6	0002-2236	HUMAN PRESCRIPTION DRUG	Trulicity		Dulaglutide	INJECTION, SOLUTION	SUBCUTANEOUS	20200903		BLA	BLA125469	Eli Lilly and Company	DULAGLUTIDE	3	mg/.5mL	GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]		N	20231231
0002-2377_bec46346-20b5-4dbe-bac3-b8564e906941	0002-2377	HUMAN PRESCRIPTION DRUG	EMGALITY		galcanezumab-gnlm	INJECTION, SOLUTION	SUBCUTANEOUS	20180927		BLA	BLA761063	Eli Lilly and Company	GALCANEZUMAB	120	mg/mL			N	20221231
0002-2980_c76a3069-8c7e-4efd-ac8e-a295f77cef89	0002-2980	HUMAN PRESCRIPTION DRUG	RETEVMO		selpercatinib	CAPSULE	ORAL	20200508		NDA	NDA213246	Eli Lilly and Company	SELPERCATINIB	80	mg/1			N	20221231
0002-3115_bec46346-20b5-4dbe-bac3-b8564e906941	0002-3115	HUMAN PRESCRIPTION DRUG	EMGALITY		galcanezumab-gnlm	INJECTION, SOLUTION	SUBCUTANEOUS	20190604		BLA	BLA761063	Eli Lilly and Company	GALCANEZUMAB	100	mg/mL			N	20221231
0002-3182_69bd3896-91f6-4960-8538-2880159588c6	0002-3182	HUMAN PRESCRIPTION DRUG	Trulicity		Dulaglutide	INJECTION, SOLUTION	SUBCUTANEOUS	20200903		BLA	BLA125469	Eli Lilly and Company	DULAGLUTIDE	4.5	mg/.5mL	GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]		N	20231231
0002-3227_6963b20c-fce1-414e-90b6-5d0730f93191	0002-3227	HUMAN PRESCRIPTION DRUG	Strattera		Atomoxetine hydrochloride	CAPSULE	ORAL	20021126		NDA	NDA021411	Eli Lilly and Company	ATOMOXETINE HYDROCHLORIDE	10	mg/1	Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]		N	20231231
0002-3228_6963b20c-fce1-414e-90b6-5d0730f93191	0002-3228	HUMAN PRESCRIPTION DRUG	Strattera		Atomoxetine hydrochloride	CAPSULE	ORAL	20021126		NDA	NDA021411	Eli Lilly and Company	ATOMOXETINE HYDROCHLORIDE	25	mg/1	Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]		N	20231231